Law360 (June 16, 2020, 5:22 PM EDT) -- Biopharmaceutical royalties company Royalty Pharma debuted strongly in public markets Tuesday after raising nearly $2.2 billion, completing the year's largest initial public offering with the help of three law firms.
Royalty Pharma plc, advised by Davis Polk & Wardwell LLP, sold 77.7 million Class A shares at $28 each late on Monday. The deal priced at the top of its range of $25 to $28 per share and raised $2.175 billion for the New York-based buyer of biopharmaceutical royalties.
Goodwin Procter LLP represented the underwriters on the IPO, while Akin Gump Strauss Hauer & Feld LLP also advised Royalty Pharma, which...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!